Redwood Bioscience Anti-HER2 Antibody-Maytansine Conjugate Patent Application EP3151830A1
Summary
The EPO published patent application EP3151830A1 by Redwood Bioscience, Inc. on April 15, 2026, covering anti-HER2 antibody-maytansine conjugates and methods of use for cancer treatment. The application names eight inventors and falls under IPC classifications A61K 47/68 and A61K 31/4045, with potential coverage across 34 European designated states including Germany, France, the United Kingdom, Italy, and Spain.
“ANTI-HER2 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF”
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.
What changed
The EPO published patent application EP3151830A1, a new pharmaceutical patent filing by Redwood Bioscience, Inc. for anti-HER2 antibody-maytansine conjugate compounds and their use in treating cancer (A61P 35/00). The application names eight inventors including David Rabuka, Aaron Albers, and Gregory DehART. The designated states cover all major European patent validation countries.
Affected parties in the pharmaceutical and biopharmaceutical sectors should note this patent publication for prior art searches and freedom-to-operate analysis, particularly companies developing ADC (antibody-drug conjugate) therapeutics targeting HER2-expressing cancers. Competitors in the oncology ADC space should review the claims for potential overlap with their own development programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-HER2 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF
Publication EP3151830A1 Kind: A1 Apr 15, 2026
Applicants
Redwood Bioscience, Inc.
Inventors
RABUKA, David, ALBERS, Aaron Edward, BARFIELD, Robyn M., DEHART, Gregory W., DRAKE, Penelope M., KUDIRKA, Romas Alvydas, GAROFALO, Albert W., McFARLAND, Jesse M.
IPC Classifications
A61K 47/68 20170101AFI20171221BHEP A61K 31/4045 20060101ALI20171221BHEP A61P 35/00 20060101ALI20171221BHEP C07K 16/32 20060101ALI20171221BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.